An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, when a causative role of the drug is implausible, suggested stepped-up ...

Alan Carr has revealed that a recent health scare left him worried he’d lose his eyesight for good. The 48-year-old comedian, ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

How Genetic Factors Are Associated with Behavioral Side Effects of GLP-1 Weight Loss Medication Glucagon-like peptide 1 ...

As Marceline Tawembi's grieving loved ones now prepare to lay her to rest, they say her story is highlighting the challenge ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have ...

The Coit House in Buffalo unveiled new artwork Friday night highlighting maternal awareness. The renowned Buffalo artist, ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...